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Background: Chronic migraine (CM) has a high impact on functional performance and quality of life (QoL). CM
also has a relevant burden on the National Health Service (NHS), however precise figures are lacking. In this pilot
study we compared the impact in terms of costs of CM and episodic migraine (EM) on the individual and on the
National Health System (NHS). Furthermore, we comparatively evaluated the impact of CM and EM on functional
capability and on QoL of sufferers.
Methods: We enrolled 92 consecutive patients attending the Pavia headache centre: 51 subjects with CM and 41
with EM. Patients were tested with disability scales (MIDAS, HIT-6, SF-36) and with an ad hoc semi-structured
questionnaire.
Results: The direct mean annual cost (in euro) per patient suffering from CM was €2250.0 ± 1796.1, against
€523.6 ± 825.8 per patient with EM. The cost loaded on NHS was €2110.4 ± 1756.9 for CM, €468.3 ± 801.8 for EM.
The total economic load and the different sub-items were significantly different between groups (CM vs. EM p = 0.001
for each value).
CM subjects had higher scores than EM for MIDAS (98.4 ± 72,3 vs 15.5 ± 17.7, p = 0.001) and for HIT-6 (66.1 ± 8.4 vs
58.7 ± 10.1, p = 0.001). The SF-36 score was 39.9 ± 14,74 for CM and 66.2 ± 18.2 for EM (p = 0.001).
Conclusions: CM is a disabling condition with a huge impact on the QoL of sufferers and a significant economic
impact on the NHS. The adequate management of CM, reverting it back to EM, will provide a dual benefit: on the
individual and on the society.
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Prevalent pain conditions impose a significant economic
impact on individuals and on society. Migraine repre-
sents a common pain disorder, with a prevalence in the
general population of 11 % [1]. The incidence of
migraine is higher in women with a peak during
productive years (between 25 and 55 years of age) in
Western countries [1, 2], which translates into very high
costs of migraine, for both the individual and the society.
As a consequence, migraine is ranked among the most* Correspondence: eliana_berra@yahoo.it
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Available literature mostly refers to the episodic form of
migraine, while less is known about the economic
impact of chronic migraine (i.e. headache present in
more than 15 days/month) [4], whose prevalence varies
from 0.5 to 5.1 % of the general population [5, 6].
“Cost of illness” represents an economic evaluation
methodology and it allows to quantify the cost caused by
illnesses on the population [7]. This economic evaluation
usually considers two categories of costs: direct and in-
direct costs. Direct costs are attributable to the delivery
of medical care and include medications costs, medical
exams and physician and hospital visits. Compelling evi-
dence indicates that patients with headache in primaryle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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same gender counterparts without headache [8]. Indirect
costs include impact on functional capacity, resulting in
reduction of work and social activities induced by illness.
Indirect costs are often undervalued but they indeed
represent a problem of vast proportions, both in terms
of quality of life for individuals, and in terms of eco-
nomic loss for society.
Published data suggest that the economic impact is
higher for patients with the chronic pattern of headache
(CH) than for patients with episodic forms in United
States and in Europe. However, the estimated cost
related to headache presents a great variability in the
different studies [9–11]. This variability is due to the
different methods performed and partly to the coun-
tries and to the time period in which studies were
conducted.
The main aim of this pilot study was the comparison
of the impact in terms of costs of CM and episodic
migraine (EM) on the individual and on the National
Health System (NHS). Furthermore, we comparatively
evaluated the impact of CM and EM on functional cap-
ability and on QoL of sufferers.
Methods
The study is a cross-sectional cost-of-illness survey, con-
ducted on patients with Chronic and Episodic Migraine at-
tending the Headache Centre of the National Neurological
Institute Casimiro Mondino Foundation of Pavia, Italy.
Data was collected by means of an ad hoc questionnaire
developed by the Authors and formed by18 items sub-
divided into 4 sections: demographic and general health
and headache-related data, impact of headache on school,
work and leisure activities, use of medication (acute
or preventive treatments) and use of health resources
(consultations, investigations, and hospitalizations). The
questions were mostly categorical, although a few of them
were open-text.
Diagnostic methodology
Patients were first evaluated by two expert neurologists
(GS, NG), who collected clinical parameters and defined
the diagnosis. Subsequently, patients were asked to fill in
the questionnaire with the help of a young doctor (RDI).
The same doctor also administered the following scales
aimed at investigating the impact of headache on func-
tion and quality of life: MIDAS (Migraine Disability
Assessment) assesses headache-related disability in the
past three month and is the most frequently used dis-
ability instrument in migraine research and clinical prac-
tice [12]; HIT-6 (The Headache Impact Test) examines
impact of headache on limitation of daily performances
[13], and SF36-tm (Health Survey) investigates the qual-
ity of life [14].Study subjects
The questionnaire was administered to consecutive sub-
jects with CM (case group) and EM (control group) who
attended the Pavia Headache Centre between September
and December 2013 and who met the inclusion criteria
listed below. The diagnoses were based on the criteria of
the International Classification of Headache Disorders,
III Edition (ICHD-IIIbeta) [4].
Inclusion criteria
1- Male and female patients aged between 18 and
65 years;
2- Diagnosis of Episodic migraine or Chronic Migraine
according to the ICHD-IIIbeta;
3- Age at migraine onset < 50 years;
4- Absence of any other neurological disorders;
5- Capability to differentiate headache attacks that are
not migraine;
6- Capability and willingness to fill out the questionnaire
and to give their informed consent
Patients were excluded from the study in the case of one
or more of these conditions
1- Ongoing pregnancy or nursing;
2- Severe cardiovascular, respiratory, metabolic or
psychiatric disorders;
3- Neurological disorders different from migraine;
4- Any other disease or conditions that could compromise
the patient’s participation in the study;
5- Abuse of alcohol or other drugs;
6- Use of NSAIDs or antiepileptic drugs or antidepressant
drugs, a daily basis, for other disorders different from
migraine.
The local Ethics Committee approved the general
protocol of survey and the data management.
All participants received and signed an informed con-
sent to participate in the study.
Data analysis
Disability associated to migraine was calculated by
means of MIDAS and of HIT-6. More specifically,
MIDAS was used to calculate number of days lost due
to illness [12], while HIT-6 allowed to evaluate the glo-
bal impact of migraine in daily performances [13]. Sub-
jective perception of quality of life was investigated by
means of the SF-36 scale [14].
Direct costs were collected and aggregated in five
categories: symptomatic medications, prophylactic medi-
cations, clinical consultations, diagnostic investigations
and hospitalizations.
Table 1 Demographic and clinical features of partecipants with
Chronic (CM) and Episodic Migraine (EM)
CM EM p-value
Age 46.9 ± 9.6 48.2 ± 13.8 Ns
Sex (F/M) 45/6 30/11 Ns
Age at migraine onset 21.5 ± 8.7 23.1 ± 11.9 Ns
Duration of chronic migraine (years) 4.42 ± 7.9 - -
Days of migraine/month 21.3 ± 3.3 4.4 ± 3.1 0.001
Days of drug intake/month 20.2 ± 5.7 4.1 ± 2.6 0.001
Number of drugs intake/month 27.1 ± 20.6 4.2 ± 4.1 0.001
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ther partially subsidized by the National Health System
(NHS) or not subsidized at all, depending on pharma-
ceutical classes. Their cost was calculated by considering
each separate class and quantifying the amount of the
subsidization and the contribution required to the pa-
tient. Consultations and diagnostic investigations are
partially subsidized by NHS, their cost was therefore cal-
culated by considering separately the amount of the
subsidization provided by NHS and the contribution
required to the patient, as derived from the national and
regional formularies [15]. Hospitalizations are entirely
subsidized by the NHS and reimbursed according to
Diagnosis Related Group (DRG), a system, introduced in
Italy from 1995, that allows to classify all patients dis-
charged from a hospital in homogeneous groups for
absorption of resources committed. This aspect makes it
possible to quantify this cost absorption of resources
and thus remunerate each episode of hospitalization, in
order to control health care costs [16].
Acute and prophylactic medications used during the
previous 3 months were adjusted in order to reach an
estimate of the gross annual cost. Cost of medications
was identified from a private site for health care profes-
sionals [17].
Statistical analysis
The minimum sample size of the study was estimated
with the “Open Source Epidemiologic Statistics for
Public Health” [18]. Basing on our expertise and after an
extensive literature search, we considered meaningful a
difference in total annual cost between CM and EM of
at least €300. So the sample size was calculated using
the following parameters: confidence interval (two-sided)
95 %; power 95 %; ratio of sample size 1; mean differ-
ence €300; standard deviation €400 for CM and €350 for
EM (to take in account intra-group high variability).
The suggested minimum sample size was 82 (41 pa-
tients per group).
The Statistical Package for the Social Sciences (SPSS)
for Windows, version 21.0, was used for the statistical
analysis.
The normality of distribution of all our variables was
assessed in terms of “skewness”, “excess kurtosis” and
z-tests for both skewness and kurtosis. In addition,
the data were plotted using “Q-Q plot” to visually confirm
normality. All data showed a Gaussian distribution, so
parametric tests were chosen for the analysis.
Categorical variables were plotted in cross-tables, and
statistical significance was performed with chi-square
test. Regarding continuous variables, differences between
the two study groups (CM vs. EM) were tested with
Student’s t-test for unpaired groups. To enlighten intra-
group statistically significance between Total costs, NHScosts and private costs we used an ANOVA (analysis of
variance) test, with post hoc Bonferroni’s correction.
The level of significance was set at 0.05 (always cor-
rected if necessary) for all variables.
Results
We enrolled 92 patients, 51 subjects with CM and 41
subjects with EM, who consecutively attended the
Headache Centre of the National Neurological Institute
Casimiro Mondino Foundation of Pavia, Italy. Of the 51
CM subjects, 48 were overusing symptomatic medica-
tions and they also fulfilled criteria for medication over-
use headache (MOH).
Demographic and clinical features of participants are
summarized in Table 1.
Annual direct cost per person
When considering the 92 patients as a whole, the mean
direct cost per year was €1480.7 ± 1678.2 euros, most of
which (€1378.6 ± 1628.5, 93.1 %) was covered by NHS
subsidization.
Hospitalizations accounted for 93 % of this cost
(€797.1 ± 1166.1). The mean cost for clinical consult-
ation was lighter €101.4 ± 136.5, and it was covered for
the 59.3 % (€60.16 ± 62.2) by NHS.
The cost for investigations was €108.1 ± 172.8, covered
by NHS for the 79.7 % (€86.2 ± 137.7).
The mean cost of treatments was €474.1 ± 886.6,
which was mostly covered by NHS (€413.3 ± 870.8,
87.1 %).
The cost of treatment was split in: symptomatic medi-
cations for most of it with €370.8 ± 781.8, of which
€335.3 ± 769.7 (90.4 %) covered by the NHS, and
prophylactic therapies with €103.3 ± 347.0, of which
€77.9 ± 344.8 (75.4 %) covered by NHS.
The separate analysis of costs associated with the epi-
sodic and chronic forms, showed a total annual direct
cost was of €2250.1 ± 1796.1 euros per subject with CM
and €523.6 ± 825.8 per subjects with EM. The burden
sustained by NHS corresponded to 93.7 % of the total
amount, i.e. €2110.4 ± 1756.9 euros for CM patients, and
Berra et al. The Journal of Headache and Pain  (2015) 16:50 Page 4 of 8to 89.4 % of the total sum (i.e. €468.3 ± 801.8 euros) for
EM subjects.
The mean per patient cost for hospitalizations was of
€1242.9 ± 1251.2 for CM and €242.6 ± 753.5 euros for
EM. The mean per patient cost for clinical consultations
was €131.8 ± 163.7 for CM and €63.5 ± 79.1 for EM.
NHS covered €69.2 ± 67.9 (52.5 %) and €48.8 ± 52.9
(76.8 %), respectively.
The cost for diagnostic investigations was of €113.3 ±
163.6 for CM group covered for 85.6 % by NHS (96.9 ±
140.1), 101.6 ± 185.4 for EM group, covered for 72.3 %
by NHS (€73.4 ± 133.5).
The mean cost of treatments was €762.1 ± 1105.1 for
CM group and €115.9 ± 15.2 for EM group. NHS con-
tributed €685.1 ± 1094.1 (89.9 %) in the CM group and
€75.2 ± 133.8 (65.2 %) in the EM group.
The cost of treatment was mostly represented by
symptomatic medications in the CM group, where it
amounted to €624.3 ± 980.0 (of which 90.8 %, i.e.
567.7 ± 974.5 covered by the NHS). In the EM group, the
cost for symptomatic medications was €55.3 ± 78.2 (of
which 83.5 %, i.e. €46.2 ± 79.5 subsidized by the NHS).
All the data, with intra- and inter-groups statistical
significances, are summarized in the Table 2.
Disability
When considering the 92 patients as a whole, the mean
days of missed work/school were 35.1 ± 71.2 per year,
whereas the mean days in which the patients’ productiv-
ity at work/school was reduced by half or more, because
of headache, were 51.6 ± 82.8 per year.Table 2 Annual direct cost per patient
TOTAL AVERAGE BURDEN
TOTAL COSTS
TOTAL 1480.7 ± 1678.2
NHS 1378.6 ± 1628.5
PRI 102.1 ± 151.1
HOSPITALIZATIONS NHS 797.1 ± 1166.1
CLINICAL CONSULTATIONS
TOTAL 101.4 ± 136.5
NHS 60.16 ± 62.2
PRI 41.2 ± 110.7
DIAGNOSTIC INVESTIGATIONS
TOTAL 108.1 ± 172.8
NHS 86.2 ± 137.7
PRI 21.9 ± 39.6
SYMPTOMATIC MEDICATIONS
TOTAL 370.8 ± 781.8
NHS 335.3 ± 769.7
PRI 35.4 ± 77.0
PROPHYLACTIC DRUGS
TOTAL 103.3 ± 347.0
NHS 77.9 ± 344.8
PRI 25.5 ± 64.3
CM = Chronic Migraine, EM = Episodic Migraine, NHS = National Health System, PRI = priCM group reported 57.2 ± 87.6 days per year of missed
work/school and 82 ± 97.6 days per year with prod-
uctivity at work/school reduced by half or more be-
cause of headache. The subjects with EM, in the last
year, missed 6.8 ± 18 days of work/school (CM vs.
EM p = 0.001), and their productivity was reduced by
half or more in 13.6 ± 31.2 days of work/school (CM vs.
EM, p = 0.001).
Considering all patients, the mean score for MIDAS
was 61.5 ± 68.8, the mean HIT-6 score was 62.8 ± 9.8
and the mean score for the “General Health SF-36”
questionnaire was 51.8 ± 20.9.
The mean score for MIDAS was 98.4 ± 72.3 for CM
and 15.5 ± 17.7 for EM (CM vs. EM p = 0.001). The
mean HIT-6 score was 66.1 ± 8.4 for CM and 58.7 ± 10.1
for EM (CM vs. EM p = 0.001). The mean score for the
“General Health SF-36” questionnaire was 39.9 ± 14.7 for
CM and 66.2 ± 18.2 for EM (CM vs. EM p = 0.001).
All the data, with intra- and inter-groups statistical
significances, are summarized in the Table 3.
Discussion
The present study defines and characterizes the eco-
nomic burden of migraine in a patient population at-
tending an Italian III level headache center by providing
specific quantification of the cost associated to the epi-
sodic and chronic forms of disease.
Numerous studies conducted on American and
European populations have shown a higher economic
impact of chronic headache than episodic headache. Few
of them have focused the attention on CM. The AmericanCM EM p-value (CM vs. EM)
2250.1 ± 1796.1 523,6 ± 825.8 0.001
2110.4 ± 1756.9 468,3 ± 801.8 0.001
139.6 ± 181.1 55,3 ± 83.2 0.007
1242.9 ± 1251.2 242.6 ± 753.5 0.001
131.8 ± 163.7 63.5 ± 79.1 0.016
69.2 ± 67.9 48.8 ± 52.9 Ns
62.5 ± 139.5 14,6 ± 47.7 0.038
113.3 ± 163.6 101.6 ± 185.4 Ns
96.9 ±140.1 73.4±133.5 Ns
16.4 ± 18.7 28.2 ± 62.9 Ns
624.3 ± 980.0 55,3 ± 78.2 0.001
567.7± 974.5 46,2 ± 79.5 0.003
56.6 ± 93.4 9,0 ± 10.8 0.001
137.6 ± 452.3 60,6 ± 121.9 Ns
117.3 ± 451.4 28,9 ± 106.1 Ns
20.3 ± 60.1 31,6 ± 69.6 Ns
vate
Table 3 Indirect costs and scale scores
GLOBAL POPULATION CM EM p-value (CM vs. EM)
Days of missed work/school per year 35.1 ± 71.2 57.2 ± 87.6 6.8 ± 18.0 0.001
Days with productivity reduced by half 51.6 ± 82.8 82 ± 97.6 13.6 ± 31.2 0.001
MIDAS 61.5 ± 68.8 98.4 ± 72.3 15.5 ± 17.7 0.001
General Health – SF 36 51.8 ± 20.9 39.9 ± 14.7 66.2 ± 18.2 0.001
HIT-6 62.8 ± 9.8 66.1 ± 8.4 58.7 ± 10.1 0.001
CM = Chronic Migraine, EM = Episodic Migraine
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[19] was a 5-year, national, longitudinal survey that
involved a large population of migraineurs (14,544
subjects) with the aim to quantify the cost of trans-
formed migraine (TM), described as a chronic head-
ache (with and without medication overuse), evolving
from EM. A total of 359 patients with EM developed
TM over the 5-year observation period. The survey
showed that the average per-person annual total
costs, including direct and indirect costs, were 4.4-fold
greater for TM ($7750) compared with those who
remained episodic ($1757); per-person annual indirect
costs, calculated as lost productive time, accounted for
the majority of cost in TM ($ 5392; in EM: $977) [19]. In
this survey the data were obtained by means of a self-
administered questionnaire.
The International Burden of Migraine study (IBMS)
was a cross-sectional, web-based survey on a worldwide
population that collected data from 9.160 individuals
with EM and 555 with CM in US and Canadian popula-
tion [20] and from 5398 individuals with EM and 277 in-
dividuals with CM in European countries (UK, France,
Germany, Italy, and Spain) [21]. Participants were se-
lected assessing the International Classification of
Headache Disorders, 2nd Edition (ICHD-2) diagnostic
criteria for migraine and were classified into chronic
or episodic migraine subgroups using headache fre-
quency data. The ICHD-II criteria for CM were modified
based on available data. Indirect costs were not calcu-
lated directly, but were estimated based on the replies
contained on a questionnaire for disability and quality of
life. In the US population, the total mean headache-
related direct costs for participants with CM was $1035
over 3 months compared to $383 for patients with EM;
the cost resulted lower in the Canadian population ($471
for CM; $172 for EM). In American and Canadian popu-
lation, the IBMS study showed that there could be a dif-
ference in costs between Countries related to different
medical approaches. For example, there was a superior
preventive medication use in the American population as
compared to the Canadian population, especially for
some types of preventive drugs, i.e. antidepressant and
cardiovascular drugs; in American population, morepatients with episodic migraine were treated with a pre-
ventive therapy, and more patients with chronic migraine
were submitted to diagnostic testing than Canadian pa-
tients [20].
Also in European countries CM participants had
higher level of disability and had more provider neuro-
logical consultations, emergency department/hospital
consultations and diagnostic investigations; the total
mean medical costs were about three times higher for
CM than EM. Total mean headache-related direct costs
over 3 months were in UK €929 in CM compared to
€216 in EM, in France €394 in CM compared to €121 in
EM, in Germany €373 in CM compared to €174 in EM,
in Italy €662 in CM compared to €207 in EM, in Spain
€667 in CM compared to €273 in EM. So, among partic-
ipants with CM, the average healthcare costs over
3 months varied greatly, ranging from €373 in Germany
to €929.6 in the UK. The difference in mean total
healthcare costs between CM and EM per 3 months in
Germany was only €199.8 compared to €713.0 in the
UK, €273.0 in France, €454.9 in Italy and €394.4 in
Spain. The mean cost of care varied widely between
countries, and these results suggest that there are differ-
ences across the five European countries included in this
analysis due to a different migraine management and
perhaps to different organization of NHS and reimburse-
ments. The percentage of CM participants reporting one
or more hospitalizations for migraine was more than
twice for the UK (8.80 %) compared to any other coun-
try (0 % for France, 3.8 % for Germany, 3.6 % for Italy,
and 3.6 % for Spain). EM participants had higher rates
of symptomatic medication use in UK and Germany and
higher rates of preventive medication use in Italy and
Germany. The proportion of CM participants reporting
occipital nerve block procedures was notably higher in
the UK compared to other countries. Less than one third
of CM participants in any country reported use of
preventive medications, highlighting that many partici-
pants with CM are not receiving therapy, which may be
beneficial [18].
Country differences in direct and indirect costs of
headache have also been demonstrated in other European
surveys. The Eurolight Project [11] is a cross sectional
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study, 8412 self-administered questionnaires were collected
and data related to per-person annual direct and indirect
costs were obtained. Estimates of indirect costs used aver-
age gender-specific salary levels in industry and services in
each country, obtained from the Eurostat database [22],
and one day wage was counted as the average gross annual
earnings divided by 220 working days.
However the Project does not provide specific data on
CM, but only on chronic headache (CH) with/without
medication overuse. As regards EM, the mean per-person
annual cost was €1222, with an important variability
between European countries: in Italy €1034, Austria €885,
Lithuania €297, Luxembourg €1446, Netherlands €1524
and Spain €1425.
The present study is conducted in an Italian III-level
Headache Centre and involves a relatively small number
of subjects. At variance from other studies on large
populations, where the diagnosis and the data collec-
tion were derived from a questionnaire, here the diag-
nosis is based on the accurate clinical evaluation by an
expert neurologist and clinical and economical data
were obtained with a mixed methodology that involves
the use of an hoc questionnaire and the direct interview/
support of a young physician. Furthermore, in this
paper we provide a picture of the burden of disease
in a group of subjects that are affected by the condi-
tion enough to seek care. Most of the questionnaire-
based surveys conducted in large populations are
simply based on ICHD criteria – which only requires
5 attacks of migraine for the diagnosis- and therefore
include also subjects suffering from migraine with a
low recurrence.
In this frame of well-characterized migraineurs, our
results confirm that chronic migraine exacts an higher
economic toll compared with episodic migraine: the total
mean annual per-person direct cost is € 2250 ± 1796 for
CM and € 523 ± 825 for EM.
Our study was conducted only in Italy, so it was pos-
sible to calculate, in the framework of the direct costs,
both cost paid by the National Health System (NHS)
and cost charged to the patient.
In most American and European studies this analysis
was not conducted; regulations regarding drugs prescrip-
tion and subsidization by the National Health System
vary greatly between Countries and this condition pre-
vents to estimate subsidized/private cost in international
multicenter studies.
Our results indicate that CM exacts a higher economic
toll in direct costs both on patients and, even more
so, on the Italian NHS. In the case of CM this ac-
counts for € 2110,4 ± 1756,9 per patient/year, against
€ 139,6 ± 181,1 paid by patients themselves. The dif-
ference in annual costs of symptomatic treatmentsbetween CM and EM resulted statistically significant
when analysing either NHS or patients’ share, with a total
load of €624,3 ± 980,0 for CM (€567,7 ± 974,5 on NHS,
€56,6 ± 93,4 on patients) and of € 55,3 ± 78,2 for EM
(€46,2 ± 79,5 on NHS, €9,0 ± 10,8 on patients).
Also the cost of prophylactic therapy was higher in CM
than EM, but not statistically significant (€137,6 ± 452,3
for CH and € 60,6 ± 121,9 for EH). This finding seems to
suggest that prophylactic medications might be underused
in CM subjects.
Costs for outpatients care are higher in CM, probably
because patients with a high frequency of attacks require
to effect more frequently visits. The similar cost ob-
served between patients’ groups in terms of investigation
is only apparently surprising, since most CM patients
attending our Centre reported a chronification of mi-
graine from several years. This means that most expen-
sive investigations performed to rule out biological cause
have been performed before the observation period con-
sidered in our study (last year).
About indirect costs, our results confirm published
evidences that suggest the considerable impact of
chronic migraine on functional capacity. Recent stud-
ies have demonstrated that, in Occidental countries,
the loss of productivity caused by headache is one of
the most important problems of chronic headache
and could represents more than 50 % of the total an-
nual costs related to headache. In some of these stud-
ies, conducted on large patient populations, national
and international impact of indirect costs on the total
annual economic burden was calculate. Eurolight
Project showed that the indirect costs constituted
92 % of total costs in both tension-type headache and
migraine. In patients with tension-type headache, in-
direct costs were primarily attributable to reduced
productivity at work; in patients with migraine, they
were attributable equally to the reduced productivity
and to the number of days of absence to work [11]. In
American population costs attributable to lost pro-
ductive time accounted for the majority of the total
cost for patients with migraine (55.7 %) and to an
even greater extent for subjects who developed trans-
formed, chronic migraine (69.6 %).
As regards the impact of disease in terms of QoL, in
our study CM patients showed worse levels of physical
functioning, role limitation, fatigue and loss of energy,
social functioning and emotional status. Disrupted work
and social activities were calculates as number of days of
missed work/school and days in which patient’s prod-
uctivity at work/school was reduced by half; both re-
sults showed a significantly higher impact of CM
(57.2 ± 87.6 days per year of missed work/school and
82 ± 97.6 days per year of reduced productivity) when
compared with EM (6.8 ± 18 days of missed work/school
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EM, p < 001).
Limitations of the study
The present study was conducted in a single Italian III-
level Headache Centre and on a relatively small number
of subjects. Considering the differences, in terms of rates
of treatment programs and organizational management
between different Italian regions, the study provides in-
formation that cannot be generalized to the entire Country.
For a national quantification of costs of CM and EM, a
multicentric study conducted in different regional head-
ache centers is necessary.
As regards direct costs, our approach was not devised
for capturing costs of disorders that may be secondary
to headache or to its treatment (as gastrointestinal, hep-
atic and renal damage caused by analgesic overuse) or
comorbid; including these conditions, costs would of
course increase even further.
Furthermore, a limitation of this study is that indirect
economic costs were not analytically calculated. A gross
estimate could have been calculated using the specific
formulas proposed by Mennini et al. [7], however we felt
that a more detailed analysis of indirect cost would
require a larger population and was beyond the scope of
the present study.
Conclusions
This study confirms the high impact of migraine, espe-
cially in its chronic form, on the NHS and on patients
themselves, both in terms of economic cost and of wors-
ened quality of life.
Treatments or health interventions aimed at prevent-
ing conversion of EM into CM should be fostered and
encouraged. More varied and specific treatments for
CM, i.e. botulinum toxin or neuromodulation techniques,
should be used and diffused to treat chronicity, to pre-
vent relapses and, ultimately, to save significant re-
sources on both the National Health System and patients
themselves.
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